for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DexCom, Inc.

DXCM.OQ

Latest Trade

156.67USD

Change

2.80(+1.82%)

Volume

157,288

Today's Range

153.74

 - 

158.46

52 Week Range

105.05

 - 

178.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
153.87
Open
154.54
Volume
157,288
3M AVG Volume
18.23
Today's High
158.46
Today's Low
153.74
52 Week High
178.45
52 Week Low
105.05
Shares Out (MIL)
91.19
Market Cap (MIL)
14,030.79
Forward P/E
165.54
Dividend (Yield %)
--

Next Event

Q3 2019 DexCom Inc Earnings Release

Latest Developments

More

Court Rules That The Patents Asserted Against Dexcom Cgm Systems Are Invalid

Dexcom Reports Q2 Results

Dexcom Reports Q1 Non-GAAP Loss Per Share $0.05

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DexCom, Inc.

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Industry

Medical Equipment & Supplies

Contact Info

6340 Sequence Dr

+1.858.2000200

http://www.dexcom.com

Executive Leadership

Kevin R. Sayer

Chairman of the Board, President, Chief Executive Officer

Quentin S. Blackford

Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer, Principal Financial Officer

Jake Steven Leach

Executive Vice President, Chief Technology Officer

Donald M. Abbey

Executive Vice President - Quality and Regulatory Affairs

Andrew K. Balo

Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development

Key Stats

1.83 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.6K

2017

0.7K

2018

1.0K

2019(E)

1.4K
EPS (USD)

2016

-0.780

2017

-0.580

2018

0.300

2019(E)

0.920
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.49
Price To Book (MRQ)
20.39
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
152.54
LT Debt To Equity (MRQ)
152.46
Return on Investment (TTM)
-13.07
Return on Equity (TTM)
-11.12

Latest News

Latest News

BRIEF-DexCom Reports Q1 GAAP Loss Per Share Of $0.28

* Q1 REVENUE $184.4 MILLION VERSUS I/B/E/S VIEW $172.3 MILLION

BRIEF-FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing

* FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES

BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System

* U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM

BRIEF-Dexcom Inc Q4 GAAP Loss Per Share $0.11

* DEXCOM REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

BRIEF-DexCom Says Preliminary Q4 Revenue Was $218 Mln

* DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK

BRIEF-Dexcom announces development agreement with Lilly

* Dexcom announces development agreement with Lilly to integrate Dexcom CGM into connected diabetes ecosystem

BRIEF-Dexcom Inc reports Q3 GAAP loss per share $0.02

* Dexcom, inc. Reports record third quarter 2017 financial results

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers

BRIEF-‍Janus Henderson reports 10.2 pct passive stake in Dexcom

* Janus Henderson Group PLC reports a 10.2 percent passive stake in Dexcom Inc as of sept 30 - SEC filing Source text: (http://bit.ly/2ybb4kH) Further company coverage:

BRIEF-Fitbit and Dexcom to develop Continuous Glucose Monitoring Experience for people living with diabetes

* Fitbit and DexCom to develop Continuous Glucose Monitoring (CGM) experience for people living with diabetes

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

BRIEF-DexCom ‍publishes new study on people with type 2 diabetes

* DexCom- published new study showing type 2 diabetes people on a multiple daily injection insulin therapy benefit from use of continuous glucose monitoring Source text for Eikon: Further company coverage:

BRIEF-Dexcom Q2 revenue $170.6 mln; names new CFO

* Q2 revenue $170.6 million versus I/B/E/S view $166.3 million

BRIEF-Dexcom announces FDA approval of G5 mobile app for android devices

* Dexcom announces fda approval of g5 mobile app for android devices

BRIEF-Dexcom prices offering of $350 mln of 0.75% convertible senior notes

* Prices offering of $350 million of 0.75% convertible senior notes

BRIEF-Dexcom announces proposed offering of convertible senior notes

* Dexcom announces proposed offering of $300 million of convertible senior notes

BRIEF-DexCom appoints Richard Collins to board of directors

* DexCom appoints Richard Collins to board of directors Source text for Eikon: Further company coverage:

BRIEF-Dexcom Inc says committed to borrow $75 mln in principal amount under its existing $200 mln revolving credit facility - SEC filing

* Dexcom Inc - on February 28, 2017, co committed to borrow $75 million in principal amount under its existing $200 million revolving credit facility - SEC filing

BRIEF-Dexcom Q4 gaap loss per share $0.09

* Dexcom, inc. Reports fourth quarter and fiscal year 2016 financial results

BRIEF-Dexcom says chief financial officer to resign, effective as of April 1

* Dexcom Inc- on Feb 14 Jess Roper, chief financial officer notified Dexcom of his decision to resign, effective as of April 1, 2017 - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up